Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

France flag France · Delayed Price · Currency is EUR
0.5620
-0.0160 (-2.77%)
At close: Jan 30, 2026
-11.36%
Market Cap10.18M -9.6%
Revenue (ttm)1.74M +31.9%
Net Income6.27M
EPS0.35
Shares Out18.12M
PE Ratio1.62
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,350
Average Volume113,084
Open0.5600
Previous Close0.5780
Day's Range0.5600 - 0.5720
52-Week Range0.2800 - 0.9200
Beta-0.69
RSI50.52
Earnings DateApr 20, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 14
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

In 2024, EPA:ALOPM's revenue was 1.64 million, a decrease of -6.02% compared to the previous year's 1.74 million. Losses were -7.21 million, -10.89% less than in 2023.

Financial Statements